Drug de-escalation is primarily driven by the need to spare patients unnecessary toxicity and the associated side effects and repeated hospital visits. However, de-escalation strategies may also have the potential to reduce treatment costs.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Participation of the patient
Adherence in psychiatry
- AI in neurology
Control instead of a flood of data: AI makes big data and wearables usable
- Eosinophilic esophagitis
EoE rarely occurs in isolation
- Lung cancer with EGFR mutation
New perspectives in first-line therapy
- Sleep disorder
Sleep medicine in transition: new goals and a reassessment of old hypnotics
- Ginkgo biloba extract in the Alzheimer's mouse model
Effects on disease-associated microglia subpopulations
- "Patients W.A.I.T Indicator"
Access to medicines – how does Switzerland compare across Europe?
- Osteoporosis